News

Number of news items returned: 101 to 120 records of 397

With best wishes for the festive season - Funding Strategies Connect Dec 2016

07 December 2016

(10765 views)

With best wishes for the festive season - Funding Strategies Connect Dec 2016      Dear Readers,   In this, our final newsletter for 2016, ...

Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles

28 November 2016

(13450 views)

 Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles   "Isn’t it time the superannuation industry got real, started concentrating on ...

Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events

25 November 2016

(13411 views)

   Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events    Douglas Bucknell, Managing Director of Tailored Superannuation Solutions Ltd, has announced that ...

Nelson Resources Announce Additional Road Show Dates

25 November 2016

(13002 views)

  Nelson Resources Announce Additional Road Show Dates   The Nelson Resources team are in Sydney on Wednesday, 30th November and Thursday, 1st ...

The superannuation industry is ripe for change and disruption is here

24 November 2016

(12863 views)

" The superannuation industry is ripe for change and disruption is here" " The industry association ASFA, CEO Martin Fahy certainly thinks so ...

ASX Rule Changes - A Summary

11 November 2016

(13498 views)

  "The Australian Securities Exchange (ASX) has just released their revised rule changes that will take effect from 19 December 2016. We ...

BlueMount Capital Chinese Presentation Nov16

09 November 2016

(9421 views)

 The 'China Angle' BlueMount Capital offers a number of Chinese capabilities as shown in the slide below:     Please view the full presentation ...

Trac Group welcomes Elon Musk to roof party

08 November 2016

(8457 views)

  Trac Group welcomes Elon Musk to roof party   "Building products company Trac Group Holdings has welcomed billionaire Elon Musk’s planned expansion into ...

ASX Listing, Company Updates and Introductions - Funding Strategies Connect Nov 2016

04 November 2016

(13032 views)

ASX Listing, Company Updates and Introductions - Funding Strategies Connect Nov 2016 Dear Readers, I hope you enjoyed the Melbourne Cup festivities ...

"Get up to 50% of your export marketing costs back with Nifty Forms"

02 November 2016

(13375 views)

    "Get up to 50% of your export marketing costs back with Nifty Forms Nifty Forms is an online platform enabling startups ...

Ocular Robotics: Successful Demonstration at Army Innovation Day, Invitation to Present on Counter UAS Capabilities, Releases New Video

02 November 2016

(13378 views)

" Successful Army Innovation Day Demonstration for Ocular Robotics United States Defence Advanced Research Projects Agency (DARPA) Selects Ocular Robotics to Present ...

"Cirrena: Another long contract client signed"

01 November 2016

(13211 views)

" Cirrena signs 12 month development contract with recurring income Strong scope to offer new client other Cirrena products & services First revenues ...

"Australian Trading & Investment Corp plans 2017 capital raise ahead of longer term IPO in US - director"

01 November 2016

(12893 views)

"Australian Trading & Investment Corporation (ATIC), an Australian unlisted public financial technology company, plans to raise AUD 3m-AUD 5m (USD ...

"Nelson Resources could become attractive target amid renewed interest in gold - exec"

31 October 2016

(12726 views)

"Nelson Resources (previously Mongolian Resource Corporation), a Western Australian-based gold exploration company, could become a takeover target in 18 to 24 months ...

"OPMANTEK NAMED QUEENSLAND’S TOP ICT EXPORTER FOR THE 3RD CONSECUTIVE YEAR"

31 October 2016

(12648 views)

"After a year of outstanding international growth, Opmantek were thrilled to be recognized for the 3rd consecutive year as Queensland’s top ...

"The rise of Robo Advisors is set to be repeated in the $452 billion MySuper segment"

28 October 2016

(12957 views)

"The superannuation industry is on the cusp of significant change and Smart Defaults like Trustee Tailored Super are set to ...

Benojo - Latest News - October 2016

24 October 2016

(12977 views)

"- Benojo grows its tech capacity by hiring an ex- lead user experience designer from Microsoft - Benojo builds sales capacity ...

"The fast-paced world of Squirrel Super: a tech company at heart"

12 October 2016

(14527 views)

"Squirrel Super leads the SMSF market with flexibility and efficiency Squirrel Super (part of Squirrel Limited), which started trading in May ...

160 Macquarie St, St Lucia - Development Approved

11 October 2016

(13429 views)

"An update on St Lucia Developments luxury apartments development at 160 Macquarie Street, St Lucia. Arquis Property Group are pleased ...

ATIC Update: Round 3 Closed, Entering Global Markets - China, Continued Fin Tech Development

11 October 2016

(12294 views)

"Round 3 closed. Exploring Global Partnerships- China on target Trade via STOCKATIC ™ - evolvement of a trading platform ROBO Advice Continued outstanding outperformance ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625